|
|
Vaccine Detail
|
alpha-Gal Epitope-Engineered MUC1-Expressing PANC1 Cell Vaccine |
| Vaccine Information |
- Vaccine Name: alpha-Gal Epitope-Engineered MUC1-Expressing PANC1 Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Whole tumor cell vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: Multiple tumor-associated antigens (MUC1, CD44, CD24, ESA, others) (Deguchi et al., 2010)
- Immunization Route: Intraperitoneal injection (i.p.)
- Description: A whole tumor cell vaccine consisting of irradiated human pancreatic adenocarcinoma PANC1 cells genetically engineered to express alpha-Gal epitopes on surface glycoproteins. Upon vaccination, naturally occurring or induced anti-Gal antibodies bind to alpha-Gal epitopes on vaccine cells, forming immune complexes that enhance uptake by antigen-presenting cells via Fc receptors, leading to improved presentation of multiple tumor-associated antigens including MUC1, CD44, CD24, and ESA. Vaccination with pancreatic cancer cells (PANC1) elicited 8- to 16-fold increase in anti-MUC1 IgG (IgG1, IgG2b, IgG3 subclasses), expansion of MUC1-specific B cells (554 vs 320 per 10^6 splenocytes; P < 0.0001) and IFN-y-secreting T cells (1,238 vs 211 per 10^6 splenocytes), and antibodies against CD44+CD24+ cancer stem cells. In alpha1,3GT knockout mice challenged with MUC1-expressing B16F10 melanoma cells, the vaccine demonstrated cross-protective immunity with significant tumor growth inhibition and prolonged survival (41.4 vs 21.1 days; P = 0.003), with 75-80% survival at 30 days compared to 20% for unmodified cell vaccine (Deguchi et al., 2010).
|
| Host Response |
|
|
| References |
Deguchi et al., 2010: Deguchi T, Tanemura M, Miyoshi E, Nagano H, Machida T, Ohmura Y, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Ito T, Mori M, Doki Y, Sawa Y. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer research. 2010; 70(13); 5259-5269. [PubMed: 20530670].
|
|
